Cemiplimab-Rwlc
Last Updated: 06/30/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 28 publications
Efficacy of Neoadjuvant Cemiplimab Treatment for Cutaneous Squamous Cell Carcinoma-A Systematic Review.
Journal: International journal of molecular sciences
Published: June 16, 2025
Cosibelimab (Unloxcyt) for cutaneous squamous cell carcinoma.
Journal: The Medical letter on drugs and therapeutics
Published: February 13, 2025
CASE (CemiplimAb-rwlc Survivorship and Epidemiology): a study in advanced basal cell carcinoma.
Journal: Future oncology (London, England)
Published: January 11, 2025
Severe hypersensitivity reactions to 2 immunotherapy agents in a patient with cutaneous squamous cell carcinoma.
Journal: American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists
Published: October 19, 2024
Beyond the Label: Real-World Side Effects Experienced With FDA-Approved Drugs for Non-Melanoma Skin Cancers.
Journal: Journal of drugs in dermatology : JDD
Published: May 06, 2024
Disparities in Utilization of Immune Checkpoint Inhibitor Therapy Among Older Patients With Advanced Non-Small Cell Lung Cancer: A SEER-Medicare Analysis.
Journal: JCO oncology advances
Published: April 23, 2024
High response rate with extended dosing of cemiplimab in advanced cutaneous squamous cell carcinoma.
High response rate with extended dosing of cemiplimab in advanced cutaneous squamous cell carcinoma.
Journal: Journal for immunotherapy of cancer
Published: February 14, 2024
Images in Immunotherapy and Precision Oncology: Advanced Basal Cell Carcinoma.
Journal: Journal of immunotherapy and precision oncology
Published: December 14, 2023
Recommendations for Cost-Conscious Treatment of Basal Cell Carcinoma.
Journal: Dermatology and therapy
Published: April 20, 2023
Cemiplimab (Libtayo) for NSCLC.
Journal: The Medical letter on drugs and therapeutics
Published: April 11, 2023
Last Updated: 06/30/2026